The following terms and conditions (‘Terms’) apply to registration for, and use of, the MyeCare Program by an eyecare practice or affiliate store (the “Store”). The MyeCare Program facilitates patient access to BLENREP (belantamab mafodotin) and supports the coordination of required ophthalmic examinations (the “MyeCare Program”). The MyeCare Program is sponsored by GlaxoSmithKline Australia Pty Ltd (“GSK”) and managed by DKSH Patient Solutions Pty Ltd ABN 18 115 985 825 (formerly known as Partizan Worldwide Pty Limited) (“DKSH”) (together, “we”, “us” or “our”). References to the “MyeCare Program team” in these Terms mean DKSH staff and authorised subcontractors acting on its behalf.
Please read these Terms and the MyeCare Program Privacy Notice. If you have any questions or require additional information, please contact the MyeCare Program team on 1800 140 272
1. Use of the MyeCare Program
The Store may only access and use the MyeCare Program in accordance with these Terms and any instructions provided by the MyeCare Program team. The Store will use the secure online MyeCare Program portal (the “Portal”) to record, submit and view patient reports from ophthalmic examinations. For clarity, reporting via the Portal applies to ophthalmic examinations required prior to the first 6 doses of BLENREP; after that point, reporting is the responsibility of the eyecare professional and will occur in accordance with the established pathway/standard of care (outside the Portal). The Store must accept these Terms at the time of initial registration for access to the Portal. Continued use of the Portal following acceptance constitutes ongoing agreement to these Terms.
Where required by the Portal, the Store’s submission of patient information confirms that the Store remains bound by these Terms in respect of that submission.
The Store warrants that all eyecare professionals who conduct ophthalmic examinations or access the Portal on its behalf are appropriately registered to practice in Australia under the Health Practitioner Regulation National Law, as in force in each state and territory (“Eyecare Professionals”). The Store acknowledges and agrees that:
The MyeCare Program provides, to eligible patients who enrol in the MyeCare Program, ophthalmic examination support services as set out in the MyeCare Program materials.
The MyeCare Program is a patient assistance service and does not provide medical advice, treatment guidance, or recommendations. All clinical decisions remain the independent responsibility of the treating healthcare professional.
The MyeCare Program is not intended to influence the recommendation or prescribing of GSK products and is not a promotional program.
These Terms set out the conditions governing the participation of the Store in the MyeCare Program, including the roles and responsibilities applicable to the Store in connection with access to, and use of, the MyeCare Program for eligible patients prescribed BLENREP for their haematological condition, multiple myeloma.
These Terms also set out the applicable compliance requirements and operational parameters for the Store’s participation in the MyeCare Program, to support the safe, lawful and effective operation of the MyeCare Program.
For clarity, no financial consideration, fee or payment will be made by DKSH to the Store in connection with participation in the MyeCare Program, unless otherwise expressly agreed in writing.
As a participating Store in the MyeCare Program, the Store must: ensure that all participating Eyecare Professionals have completed the required MyeCare Program training prior to conducting ophthalmic examinations for patients undergoing treatment with BLENREP or accessing the Portal; accept patient referrals made through the MyeCare Program; facilitate timely appointment bookings and clinical reporting in accordance with the MyeCare Program requirements; and take reasonable steps to minimise patient out‑of‑pocket costs, where applicable and clinically appropriate, within the Store’s discretion and in accordance with MyeCare Program requirements.
As administrators of the MyeCare Program, DKSH will: Program Administration – Oversee the operation of the MyeCare Program, including patient enrolment, coordination, and ongoing program management*.
Referral Management – Manage the administration and coordination of patients referred by prescribing healthcare professionals, including processing referrals and arranging eyecare referrals to participating Stores.
Training Provision – Provide training materials to Eyecare Professionals on the BLENREP treatment, associated patient needs, and clinical reporting requirements.
Booking Facilitation – Use the Store public website or phone line to arrange timely appointments on behalf of referred patients.
Data Handling – Only share patient or prescribing healthcare professional information that is required to administer the MyeCare Program, ensuring that such information and any data are transferred using the Portal and DKSH’s secure GUARDIAN CRM, using secure methods consistent with industry best practice.
Compliance Oversight – Monitor adherence to legal, privacy and data security requirements relevant to administration of the MyeCare Program.
*Supply of preservative-free eye drops directly to patients: As part of the MyeCare Program, DKSH will supply patients with an initial 12-week course of preservative-free eye drops in accordance with the MyeCare Program materials.
Store responsibilities. As a participating Store in the MyeCare Program, the Store will:
Referral Acceptance – Accept referrals of eligible patients for eyecare services.
Booking Support – Facilitate use of the Store’s public booking channels (where applicable) to enable timely appointment scheduling for referred patients.
Training Participation – Ensure the Store’s Eyecare Professionals complete the provided training on BLENREP treatment, patient needs, and clinical reporting protocols.
Portal registration – Register to use the Portal to record, submit and view patient reports from ophthalmic examinations.
Examination and reporting – Ensure that slit lamp and visual acuity examinations are conducted by appropriately qualified Eyecare Professionals, and that examination findings are documented using the Store’s existing clinical systems and communicated to the prescribing healthcare professional via the Portal, using the required MyeCare Program reporting forms, in a timely manner.
For clarity, the Portal reporting described above applies to ophthalmic examinations required prior to the first 6 doses of BLENREP; after that point, reporting is the responsibility of the Eyecare Professional and will occur in accordance with the established pathway/standard of care.
Cost Minimisation – Take reasonable steps to minimise patient out‑of‑pocket costs, where applicable and permitted, including, where clinically appropriate and the patient is eligible, the lawful use of relevant Medicare Benefits Schedule (MBS) item codes for initial and follow‑up appointments, in accordance with applicable Medicare rules and guidance. Nothing in this clause requires the Eyecare Professional to submit a Medicare claim or affects the Eyecare Professional’s independent clinical or billing judgment.
Compliance & Standards Ensure that services provided in connection with the MyeCare Program are delivered in accordance with all applicable professional, legal and privacy obligations, as well as the Store’s internal policies and procedures.
Data Security – Maintain the confidentiality and security of any personal or health information within the Store’s control, in accordance with applicable privacy and health records legislation and the Store’s data protection protocols and promptly notify DKSH of any actual or suspected data breach relating to the MyeCare Program.
Each party must comply with all applicable laws, regulations and professional standards in Australia that apply to it in connection with the MyeCare Program, including, without limitation, the Health Practitioner Regulation National Law (as in force in each state and territory), the Therapeutic Goods Act 1989 (Cth), the Health Insurance Act 1973 (Cth), and relevant state and territory health records legislation.
Each party must also comply with the Privacy Act 1988 (Cth), including the Australian Privacy Principles (APPs), and any applicable state or territory privacy laws, as well as, where applicable, the Australian Health Practitioner Regulation Agency (AHPRA) Guidelines for Advertising Regulated Health Services and the Therapeutic Goods Advertising Code.
Each party must implement and maintain appropriate technical and organisational measures to protect personal and health information within its control, including measures designed to prevent unauthorised access, use, disclosure, alteration or destruction of such information.
Without limiting the foregoing:
DKSH is responsible for implementing appropriate security measures in respect of the systems and infrastructure it uses to administer the MyeCare Program, including the Portal; and
the Store is responsible for implementing appropriate access controls, data protection measures and information security practices within its own systems, including restricting Portal access to authorised personnel only who have a need for access in connection with the MyeCare Program.
DKSH administers the MyeCare Program. By registering the Store to use the MyeCare Program, and providing information through the Portal (including details of Eyecare Professionals who access/use the Portal on the Store’s behalf), the Store consents to, and procures the relevant Eyecare Professionals’ consent to, DKSH collecting, using, storing, transferring and disclosing the Store’s information and such Eyecare Professional information in accordance with these Terms, the MyeCare Program Privacy Notice available at https://www.myecare.com.au/en/privacy-notice, and the Privacy Act 1988 (Cth).
Patient personal information is not shared with GSK except where required for adverse event (AE) or health and safety information (HSI) reporting and where the relevant patient consent has been obtained (where required). In such circumstances, only the information required to meet GSK’s regulatory obligations will be disclosed. De‑identified and aggregated data may be provided to GSK for governance and compliance purposes.
The Store is responsible for collecting, storing, using and disclosing patient personal and health information within its control in accordance with its own privacy policy and data security protocols, and in compliance with all applicable privacy, health records and data protection laws, including the Privacy Act 1988 (Cth) and the Australian Privacy Principles (APPs).
The Store must ensure that authorised personnel will only access and review patient personal and health information through the Portal strictly on a need to know basis and solely for the purpose of providing care to the relevant patient in connection with the MyeCare Program.
The Store must not disclose patient personal information to GSK and must only share such information with DKSH through the Portal (or otherwise as directed by the MyeCare Program team), and only where the relevant patient consent has been obtained.
The Store must use the Portal to record, submit and share patient reports from ophthalmic examinations conducted for patients enrolled in the MyeCare Program (and only to the extent required for the MyeCare Program). Where personal or health information is shared between the parties (whether via the Portal or any other permitted channel), such information must be transferred using secure methods consistent with industry best practice.
The Store is responsible for preventing, detecting and managing any unauthorised access, use or disclosure of information within its control, and for promptly notifying DKSH (within 72 hours of becoming aware) of any actual or suspected data breach relating to the MyeCare Program. The Store must cooperate with DKSH in relation to any investigation, and must comply with any reporting, notification and remediation obligations required under applicable law in relation to any such data breach.
If there are any questions, concerns or complaints regarding the handling of privacy matters in connection with the MyeCare Program, the MyeCare Program team can be contacted on 1800 140 272 or at support@myecare.com.au.
“Confidential Information” includes any non‑public business, technical, personal, professional, Eyecare Professional, patient or MyeCare Program‑related information disclosed in connection with the MyeCare Program or under these Terms.
The Store must keep all Confidential Information secure and must not disclose such information to any third party, except where required by law or permitted in writing by the disclosing party.
These confidentiality obligations survive termination or expiry of these Terms and remain in force for a period of seven (7) years thereafter.
The Store must perform its obligations under these Terms with reasonable care and skill and in accordance with applicable professional standards.
The Store is responsible for the acts and omissions of its personnel and contractors in connection with the MyeCare Program.
The Store must maintain, at its own cost, appropriate and current insurance coverage, including:
professional indemnity insurance covering the acts and omissions of its personnel and contractors in connection with the MyeCare Program; and
public liability insurance covering liability for personal injury, death or property damage arising from its activities under these Terms.
The Store must provide evidence of such insurance upon reasonable request and must ensure that such insurance coverage is maintained and does not lapse for the duration of its participation in the MyeCare Program.
To the extent permitted by law, neither party will be liable to the other for any indirect or consequential loss, except to the extent that such loss arises from a breach of confidentiality obligations, privacy obligations or willful misconduct.
The Store’s registration to access the MyeCare Program Portal will continue for the duration of the MyeCare Program, unless earlier terminated in accordance with these Terms or until the Store elects to opt out. The Store may opt out at any time by contacting the MyeCare Program team on 1800 140 272 or by email at support@myecare.com.au.
DKSH may suspend or cancel the Store’s access to the MyeCare Program where required for regulatory, safety, operational or MyeCare Program related reasons. DKSH will use reasonable efforts to provide notice to the Store where practicable.
Without limiting any other rights, DKSH may suspend or terminate the Store’s access to the MyeCare Program with immediate effect by written notice if the Store materially breaches these Terms and, where the breach is capable of remedy, fails to remedy that breach within a reasonable period after being notified.
Where the Store elects to opt out of the MyeCare Program, or where a patient’s care is otherwise transferred to another eyecare provider, the Store must notify the MyeCare Program team to enable patient records to be updated and to facilitate continuity of care. Where a patient is transferred, the receiving eyecare provider will be required to register for the MyeCare Program and agree to the applicable terms and conditions before MyeCare Program supply and support services can continue.
If the Store’s registration to the MyeCare Program ends for any reason, the MyeCare Program team will contact affected patients to explain the impact on their ongoing support and supply arrangements and will assist, where appropriate, with a safe and timely transition of care in accordance with clinical direction.
If a dispute arises in connection with the MyeCare Program or these Terms, the parties will first seek to resolve the matter through good‑faith discussions between their respective operational representatives.
If the dispute is not resolved at an operational level, it may be escalated to senior management of each party for further consideration.
If the dispute remains unresolved, the parties may agree to refer the matter to mediation before commencing legal proceedings, except where urgent injunctive or equitable relief is sought.
Accepting these Terms does not create a partnership, agency or employment relationship between the Store and the MyeCare Program, GSK or DKSH.
All intellectual property rights in the MyeCare Program, the Portal, and any materials made available as part of the MyeCare Program remain the property of DKSH, GSK or their licensors. Subject to compliance with these Terms, the Store is granted a non‑exclusive, non‑transferable, revocable licence to access and use the Portal and MyeCare Program materials solely for the purpose of participating in the MyeCare Program. The Store must not copy, modify, distribute or use any MyeCare Program materials for any other purpose without prior written consent.
The Store is responsible for all costs associated with performing services in connection with the MyeCare Program, unless otherwise expressly agreed in writing.
These Terms are governed by the laws of the Australian state or territory in which the Store is located. Each party submits to the non‑exclusive jurisdiction of the courts of the Australian state or territory in which the Store is located.
DKSH reserves the right to modify these Terms from time to time, including the MyeCare Program eligibility requirements. Reasonable efforts will be made to notify the Store of material changes to these Terms, for example by email. The Store may elect not to accept an amendment by ceasing participation in the MyeCare Program (including by ceasing use of the Portal) before the amendment takes effect. Continued access to or use of the MyeCare Program, including the Portal, after any such changes take effect constitutes acceptance of the updated Terms.
DKSH may also update, improve or otherwise modify the software, services or operational features of the MyeCare Program (including the Portal) from time to time.
The MyeCare Program may be terminated at any time at the direction of GSK for regulatory, safety or other reasons GSK reasonably considers necessary. Following Program termination, no new patients will be enrolled.
To the extent legally permitted following termination of the MyeCare Program, patients already enrolled at the time of termination may continue to receive MyeCare Program support and BLENREP supply in accordance with clinical direction, until treatment is clinically discontinued, the patient no longer meets eligibility criteria, or disease progression occurs.
If you have any questions about the MyeCare Program or these Terms, please contact us by phone on 1800 140 272 or by email at support@myecare.com.au.
For product information or AE/HSI reporting for BLENREP, contact GSK Medical Information: 1800 033 109 or MEL.Australia-Product-Safety@gsk.com.